Welcome Guest
Home » Reports » Antibody Drug Conjugates Market (4th Edition), 2017-2030

Antibody Drug Conjugates Market (4th Edition), 2017-2030

Published: Oct 27, 2017
Pages: 556
Product Code: RA10093
License Type :  (Learn More)

Since the first approval of MYLOTARG™ in 2000 and its subsequent withdrawal in the year 2010, the ADC market has evolved considerably. In the last seven years, the market has witnessed an increasing interest from drug developers and healthcare investors alike. Post the commercialization of ADCETRIS® in 2011 and KADCYLA® in 2013, there was a temporary, but evident, decline in the popularity of ADCs. This was attributed to the fact that no new ADC candidates were approved after 2013 and the focus had shifted to other novel therapies, such as immune checkpoint inhibitors and T-cell therapies. However, the recent approval of BESPONSA® and re-approval of MYLOTARG™ has renewed the interest of stakeholders in the domain. This growing popularity and potential of ADCs can also be correlated with an exponential increase in the number of patents that have been filed; the cumulative number has increased from 1,395 patents in 2009 to 10,208 patents in the first half of 2017.

 

While there are close to 200 ADCs in clinical / preclinical stages of development, the field is currently going through a gradual transition. The industry is shifting from relying on conventional technologies to newer approaches for generating ADCs. This transition has paved way for several well-funded start-ups, which offer novel conjugation approaches, more potent warheads and modified linker technologies. In addition, the ADCs are now being evaluated in combination with several other novel therapies, such as immune checkpoint inhibitors, epigenetic modulators and monoclonal antibodies. 

 

  • Synopsis
  • Table of
    Contents
  • List of
    Figures
  • List of
    Tables
  • Listed Companies
  • Sample
    Pages
  • Download Brochure

 

The ‘Antibody Drug Conjugates Market (4th Edition), 2017-2030’ report provides a comprehensive study on the current landscape of ADCs, featuring an elaborate discussion on the future potential of this evolving market. The field has captured the interest of several drug developers, both small and large companies. While more than half of these pipeline candidates are in the discovery / preclinical stages, around 10% of candidate therapies are presently in advanced stages (phase II and above); we anticipate the market to witness continued growth in the next 5-10 years. Amongst other elements, the report features:

  • A discussion on the pipeline of ADCs along with information on the developers / technology providers, phase of development of candidate therapies, drug targets, therapeutic indications, and the types of linkers and payloads / warheads used.
  • Identification of the most commonly targeted therapeutic indications and details of the ADCs being developed against them. The study highlights the key epidemiological facts about the diseases and also lists the currently available treatment options.
  • Extensive review on the key opinion leaders (KOLs) in the field of ADCs; the report contains a detailed 2X2 analysis to assess the relative experience of certain KOLs. It also contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers.
  • An assessment of the various therapies that are being evaluated in combination with ADCs; the study also presents the likely evolution of these therapies across different therapeutic indications.
  • Elaborate profiles of clinical stage companies and their respective product portfolios; each profile features an overview of the company, its financial performance, product portfolio, and detailed information on advanced stage pipeline candidates (featuring a drug overview, clinical development plan and clinical trial results).
  • An analysis of the partnerships that have been established in the recent past, covering R&D collaborations, license agreements, mergers and acquisitions, manufacturing and service agreements, and other relevant agreements.
  • An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants, capital raised from IPOs and subsequent offerings received by companies that are focused in this area. Moreover, the report features a detailed study on the various grants that have been awarded to research institutes in this field.
  • A review of the evolution of ADC conjugation technologies, highlighting the various approaches that have been adopted across different generations. This section also highlights the competition between contemporary technology platforms.
  • An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs. The study presents findings from various ADC studies in different animal models. The report presents an analysis of the different methods used in estimating FIH doses. In addition, it presents possible FIH starting doses and the estimated dose escalations required to reach human maximum tolerated dose (MTD).
  • A detailed analysis of the patents that have recently been filed related to ADCs. The study also highlights the emerging trends in innovation and identifies the key players involved. In addition, it presents a high-level view on the valuation of these patents.
  • A detailed case study on ADC contract manufacturers, highlighting the prevalent and emerging trends in ADC manufacturing.

 

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2017-2030. The research, analysis and insights presented in this report include potential sales of ADCs that are currently marketed or are in the late stages of development. To account for the uncertainties associated with the development of novel ADCs and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

                                      

The opinions and insights presented in the report were influenced by discussions with senior stakeholders in the industry. These include Alan Burnett (Professor, School of Medicine, James Cardiff University), Aldo Braca, (Chief Executive Officer, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Anonymous (Chief Executive Officer, Leading CMO), Christian Bailly (Head of CDMO, Pierre Fabre), Christian Rohlff, (Founder and CEO, Oxford BioTherapeutics), Anonymous (Director, Business Development, Leading CMO), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (ADC R&D, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer, Syndivia), Stacy McDonald (Group Product Manager) and Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions). All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

 

 

Example Highlights

  1. Close to 200 ADCs are currently being developed across various stages of development for a diverse range of indications. Around 60% of these drugs are in the preclinical / discovery stages.
  2. Of the clinical stage candidates, more than 12% are being developed for breast cancer, while around 10% are being developed for the treatment of NHL. Candidates targeting AML and multiple myeloma together occupy 14% (7% each) of the clinical pipeline.
  3. Around 44% of the clinical ADCs are based on auristatins (29%) and maytansinoids (15%) based cytotoxic payloads. Several highly potent payloads are being evaluated in early stages of development.
  4. Close to 50% of the total ADC clinical trials (completed / recruiting) are evaluating ADCs in combination with other therapies. In the last two years, several novel combinations have been studied with ADCs; these include combinations with PI3K inhibitors, TYK inhibitors, BTK inhibitors, CDK inhibitors, HDAC inhibitors and EGFR inhibitors
  5. More than half of the ADCs in the current clinical pipeline are being developed using the technologies provided by Seattle Genetics and ImmunoGen; however, several small sized companies have emerged in last few years, offering novel technology platforms. Some of the approaches that have been adopted for the development of third generation ADC conjugation platforms include (in alphabetical order) avoiding / limiting retro-Michael drug de-conjugation (Kyowa Hakko Kirin, MedImmune, Pfizer, ProLynx, Seattle Genetics, Syndivia), cysteine re-bridging (Abzena, Igneica Biotherapeutics, University College London / ThioLogics), enzyme-assisted ligation (Catalent / Redwood, Innate Pharma, LegoChem Biosciences, NBE Therapeutics, Pfizer, Sanofi, Tubulis Technologies, ProBioGen), glycan re-modelling (Philogen, Seattle Genetics, Sanofi, Synaffix, University of Georgia, US National Cancer Institute), and ligation at Fab nucleotide-binding site (Meditope Biosciences, University of California).
  6. Over 10,000 patents, related to ADCs, have been filed in last decade alone. ImmmunoGen, Genentech, Seattle Genetics and Immunomedics were the first to enter this domain, and currently have the highest number of patents related to ADCs. Of these, Genentech has the maximum number of international patents (55%). Other leading players include (in decreasing order of number of patents) Roche, Novartis, AbbVie, Pfizer, Amgen, Immunomedics and University of California.
  7. The innovation in this domain is also being driven by academic / research institutes. In last five years, close to 80 academic grants have been awarded to various such institutes in the US alone. Majority of the grants have been awarded for research projects (29%), followed by investigator-initiated intramural research projects (22%) and exploratory / development grants (12%). Around 15% of the grants are Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grants.
  8. Around 100 funding instances, worth USD 2.5 billion, to support research and development in ADCs have been reported in last decade. 5AM Ventures, South East Growth Fund & Management, Oxford Capital Partners, CTI Life Sciences Fund, SV Life Sciences and Alta Partners have emerged as some of the prominent investors (in terms of number of funding instances). Moreover, since 2010, more than 110 partnerships have been inked in the ADC space.
  9. With close to 20 drugs, that are either approved or are in late stages of clinical development (phase II and above), the ADCs therapeutics market is anticipated to grow at a CAGR to 19.4% between 2017 and 2030. The currently marketed ADCs target breast cancer and various forms of Hodgkin’s lymphoma. With approval of additional ADCs, in 2030, close to 55% of the market is likely to be driven by four indications, namely breast cancer (22%), lung cancer (15%), Hodgkin's lymphoma (10%) and melanoma (8%).

 

 

Research Methodology

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

 

 

The secondary sources of information include

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

 

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

 

 

Chapter Outlines

Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the likely evolution of the ADCs market in the short-mid and long term.

 

Chapter 3 provides a general introduction to ADCs. In this section, we have discussed, in detail, the concept of ADC, its components, mechanisms of action and advantages over traditional targeted therapies. The chapter also presents a brief description of the Absorption, Distribution, Metabolism and Excretion (ADME) properties of the various ADCs in development.

 

Chapter 4 provides a comprehensive overview of the market landscape of ADCs under development (clinical and preclinical). This chapter includes information related to these candidates, along with their current phase of development, key target indications, developer companies and the most common types of cytotoxins and linkers used. The chapter also highlights the various ADCs that have been discontinued over the last few years.

 

Chapter 5 provides an extensive list of the key opinion leaders (KOLs) in the field of ADCs. It contains schematic representations of world maps highlighting the geographical locations of these eminent scientists / researchers. The chapter presents a detailed 2X2 analysis to assess the relative experience of certain KOLs based on the number of clinical studies they participated in and the highest phase of development they investigated.

 

Chapter 6 identifies the most commonly targeted therapeutic indications and features brief discussions on the ADCs being developed against them. It highlights the key epidemiological facts of the various disorders and lists the currently available treatment options.

 

Chapter 7 presents elaborate profiles of clinical stage companies and drugs; each profile features an overview of the company, its financial performance and product portfolio, including detailed information on advanced stage pipeline candidates (featuring a drug overview, mechanism of action, information on clinical trials and key clinical trial results).

 

Chapter 8 features an elaborate discussion and analysis of the various collaborations and partnerships that have been inked amongst players in this market. We have also highlighted the key players, the different partnership models (such as R&D agreements, technology / product licensing, product development and commercialization agreements, mergers / acquisitions, and clinical trial collaborations) and the most common forms of deals / agreements that have been established in this domain.

 

Chapter 9 presents details on various investments received by companies that are focused on development of ADCs. It also includes an analysis of the funding instances that have taken place in last ten years, highlighting the growing interest of the venture capital community and other strategic investors in this market.

 

Chapter 10 provides a detailed analysis of the academic grants that have been awarded in this field. In addition to highlighting various key funding institutes, the chapter provides various indications and molecular targets across which, majority of the research work is currently focused.

 

Chapter 11 features an overview of the various therapies being evaluated in combination with ADCs. It also features a study of the likely evolution of these therapies across different therapeutic indications.

 

Chapter 12 features an elaborate discussion and competitive analysis of the various ADC conjugation approaches. This chapter also features an overview of the evolution of these technologies in addition to highlighting the competition between contemporary technology platforms.

 

Chapter 13 provides an overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection. The chapter presents insights from recently conducted studies in different animal models, analyzing the different methods used in estimating FIH doses. In addition, it presents possible FIH starting doses and the estimated dose escalations required to reach human maximum tolerated dose (MTD). The chapter highlights different types of ADC related toxicities observed in animal models, highlighting the doses at which these toxicities were observed.

 

Chapter 14 provides a detailed analysis of the patents that have been filed in the ADCs space. The study highlights emerging trends in the patents that have been filed and identifies the key players that are driving the innovation in this area. It also presents a high-level view on the valuation of these patents.

 

Chapter 15 provides details on the various players that offer contract manufacturing services for ADCs, or possess the necessary capabilities and infrastructure to manufacture such products in-house. The chapter illustrates the manufacturing capabilities of different contract manufacturers highlighting the various recent expansion plans and other agreements inked between companies.

 

Chapter 16 presents a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. It includes future sales projections of ADCs that are either marketed or are in advanced stages of clinical development (phase II and preregistration). The sales potential and growth opportunity were estimated based on the target patient population, likely adoption rates, existing / future competition from other drug classes and the likely price of products. The chapter also presents a detailed market segmentation on the basis of key indications, payloads and linkers.

 

Chapter 17 provides a detailed analysis capturing the key parameters and trends that are likely to influence the future of the ADCs market within the biopharmaceutical industry, under a comprehensive SWOT framework.

 

Chapter 18 summarizes the overall report. The chapter provides a list of the key takeaways and presents our independent opinion on the ADC market, based on the research and analysis described in the previous chapters.

 

Chapter 19 is a collection of interview transcripts of the discussions held with key stakeholders in this market. In this chapter, we have presented the details of our conversations with Alan Burnett (Professor, School of Medicine, James Cardiff University), Aldo Braca, (Chief Executive Officer, BSP Pharmaceuticals), Anthony DeBoer (Director, Business Development, Synaffix), Anonymous (Chief Executive Officer, Leading CMO), Christian Bailly (Head of CDMO, Pierre Fabre), Christian Rohlff, (Founder and CEO, Oxford BioTherapeutics), Anonymous (Director, Business Development, Leading CMO), John Burt (Chief Executive Officer, Abzena), Laurent Ducry (ADC R&D, Lonza), Mark Wright (Site Head, Grangemouth, Piramal Healthcare), Sasha Koniev (Chief Executive Officer, Syndivia), Stacy McDonald (Group Product Manager) and Jennifer L. Mitcham (Director, Business Development, Catalent Pharma Solutions).

 

Chapter 20 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

 

Chapter 21 is an appendix, which provides the list of companies and organizations mentioned in the report. 

 

 

 

 
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Chapter Overview
3.2. Evolution of Cancer Treatment
3.3. Cancer Treatment Methods
3.3.1. Surgery
3.3.2. Radiation Therapy
3.3.3. Chemotherapy
3.3.4. Targeted Therapies
3.4. Monoclonal Antibodies to Treat Cancer
3.5. Essential Components of Antibody Drug Conjugates (ADCs)
3.5.1. Antibody
3.5.2. Cytotoxin
3.5.3. Linker
3.6. Advantages of ADCs over Traditional Therapeutics
3.7. ADCs, Monoclonal Antibodies and Small Molecule Drugs: Comparison of Key Properties
3.8. ADME Properties of ADCs
3.8.1. Absorption
3.8.2. Distribution
3.8.3. Metabolism and Elimination
 
4. MARKET OVERVIEW
4.1. Chapter Overview
4.2. ADCs: Clinical Pipeline
4.2.1. ADCs Clinical Pipeline: Distribution by Phase of Development
4.2.2. ADCs Clinical Pipeline: Distribution by Indication
4.2.3. ADCs Clinical Pipeline: Distribution by Target
4.2.4. ADCs Clinical Pipeline: Distribution by Type of Linker
4.2.5. ADCs Clinical Pipeline: Distribution by Type of Warhead
4.2.6. ADCs Clinical Pipeline: Distribution by Technology Providers
4.2.7. ADCs Clinical Pipeline: Distribution by Targets and Indication
4.2.8. ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
4.2.9. ADCs Clinical Pipeline: Discontinued Drugs
4.3. ADCs: Preclinical Pipeline
4.3.1. ADCs Preclinical Pipeline: Distribution by Key Players
 
5. KEY OPINION LEADERS
5.1. Chapter Overview
5.2. Current Research Landscape
5.2.1. ADCETIRS®: Key Opinion Leaders
5.2.2. KADCYLA®: Key Opinion Leaders
5.2.3. MYLOTARG™: Key Opinion Leaders
5.2.4. Other ADCs: Key Opinion Leaders
5.3. Most Prominent Key Opinion Leaders
 
6. KEY THERAPEUTIC AREAS
6.1. Chapter Overview
6.2. Hematological Malignancies
6.2.1. Leukemias and Lymphomas
6.2.1.1. Leukemia: Introduction and Epidemiology
6.2.1.1.1. Acute Myeloid Leukemia
6.2.1.1.2. Chronic Myeloid Leukemia
6.2.1.1.3. Acute Lymphocytic Leukemia
6.2.1.1.4. Chronic Lymphocytic Leukemia
6.2.1.2. Lymphoma: Introduction and Epidemiology
6.2.1.3. Current Treatment Landscape
6.2.1.4. ADCs for Leukemia / Lymphoma
 
6.2.2. Multiple Myeloma
6.2.2.1. Introduction and Epidemiology
6.2.2.2. Current Treatment Landscape
6.2.2.3. ADCs for Multiple Myeloma
 
6.3. Solid Tumors
6.3.1. Metastatic Melanoma
6.3.1.1. Introduction and Epidemiology
6.3.1.2. Current Treatment Landscape
6.3.1.3. ADCs for Metastatic Melanoma
 
6.3.2. Lung Cancer
6.3.2.1. Introduction and Epidemiology
6.3.2.2. Current Treatment Landscape
6.3.2.3. ADCs for Lung Cancer
 
6.3.3. Bladder Cancer
6.3.3.1. Introduction and Epidemiology
6.3.3.2. Current Treatment Landscape
6.3.3.3. ADCs for Bladder Cancer
 
6.3.4. Kidney Cancer
6.3.4.1. Introduction and Epidemiology
6.3.4.2. Current Treatment Landscape
6.3.4.3. ADCs for Kidney Cancer
 
6.3.5. Ovarian Cancer
6.3.5.1. Introduction and Epidemiology
6.3.5.2. Current Treatment Landscape
6.3.5.3. ADCs for Ovarian Cancer
 
6.3.6. Breast Cancer
6.3.6.1. Introduction and Epidemiology
6.3.6.2. Current Treatment Landscape
6.3.6.3. ADCs for Breast Cancer
 
6.3.7. Glioblastoma
6.3.7.1. Introduction and Epidemiology
6.3.7.2. Current Treatment Landscape
6.3.7.3. ADCs for Glioblastoma
 
6.3.8. Colorectal Cancer
6.3.8.1. Introduction and Epidemiology
6.3.8.2. Current Treatment Landscape
6.3.8.3. ADCs for Colorectal Cancer
 
6.3.9. Prostate Cancer
6.3.9.1. Introduction and Epidemiology
6.3.9.2. Current Treatment Landscape
6.3.9.3. ADCs for Prostate Cancer
 
7. COMPANY AND DRUG PROFILES
7.1. Chapter Overview
7.2. AbbVie
7.2.1. Company Overview
7.2.2. Financial Performance
7.2.3. Pipeline Overview
7.2.3.1. ABT-414
7.2.3.1.1 Drug Overview
7.2.3.1.2. Mechanism of Action
7.2.3.1.3. Clinical Development Status
7.2.3.1.4. Key Clinical Trial Results
7.2.4. Recent Collaborations
 
7.3. Astellas Pharma
7.3.1. Company Overview
7.3.2. Financial Performance
7.3.3. Pipeline Overview
7.3.3.1. ASG-22ME
7.3.3.1.1. Drug Overview
7.3.3.1.2. Mechanism of Action
7.3.3.1.3. Clinical Development Status
7.3.3.1.4. Key Clinical Trial Results
7.3.3.2. ASG16-M8F
7.3.3.2.1. Drug Overview
7.3.3.2.2. Mechanism of Action
7.3.3.2.3. Clinical Development
7.3.3.2.4. Key Clinical Trial Results
7.3.4. Recent Collaborations
 
7.4. Bayer HealthCare
7.4.1. Company Overview
7.4.2. Financial Performance
7.4.3. Pipeline Overview
7.4.3.1. BAY 94-9343
7.4.3.1.1. Drug Overview
7.4.3.1.2. Mechanism of Action
7.4.3.1.3. Clinical Development Status
7.4.3.1.4. Key Clinical Results
7.4.4. Recent Collaborations
 
7.5. Biotest Pharmaceuticals
7.5.1. Company Overview
7.5.2. Financial Performance
7.5.3. Pipeline Overview
7.5.3.1. BT-062
7.5.3.1.1. Drug Overview
7.5.3.1.2. Mechanism of Action
7.5.3.1.3. Clinical Development Status
7.5.3.1.4. Key Clinical Trial Results
7.5.4. Recent Collaborations
 
7.6. Celldex Therapeutics
7.6.1. Company Overview
7.6.2. Financial Performance
7.6.3. Pipeline Overview
7.6.3.1. CDX-011
7.6.3.1.1. Drug Overview
7.6.3.1.2. Mechanism of Action
7.6.3.1.3. Clinical Development Status
7.6.3.1.4. Key Clinical Trial Results
7.6.4. Recent Collaborations
 
7.7. ImmunoGen
7.7.1. Company Overview
7.7.2. Financial Performance
7.7.3. Pipeline Overview
7.7.3.1. IMGN853
7.7.3.1.1. Drug Overview
7.7.3.1.2. Mechanism of Action
7.7.3.1.3. Clinical Development Status
7.7.3.1.4. Key Clinical Trial Results
7.7.3.2. IMGN529 / Debio1562
7.7.3.2.1. Drug Overview
7.7.3.2.2. Mechanism of Action
7.7.3.2.3. Clinical Development Status
7.7.3.2.4. Key Clinical Results
7.7.3.3. SAR3419
7.7.3.3.1. Drug Overview
7.7.3.3.2. Mechanism of Action
7.7.3.3.3. Clinical Development Status
7.7.3.3.4. Key Clinical Trial Results
7.7.4. Collaborations
 
7.8. Immunomedics
7.8.1. Company Overview
7.8.2. Financial Performance
7.8.3. Pipeline Overview
7.8.3.1. IMMU-130
7.8.3.1.1. Drug Overview
7.8.3.1.2. Mechanism of Action
7.8.3.1.3. Clinical Development Status
7.8.3.1.4. Key Clinical Trial Results
7.8.3.2. IMMU-132
7.8.3.2.1. Drug Overview
7.8.3.2.2. Mechanism of Action
7.8.3.2.3. Clinical Development Status
7.8.3.2.4. Key Clinical Trial Results
7.8.4. Recent Collaborations
 
7.9. Progenics Pharmaceuticals
7.9.1. Company Overview
7.9.2. Financial Performance
7.9.3. Pipeline Overview
7.9.3.1. PSMA ADC
7.9.3.1.1. Drug Overview
7.9.3.1.2. Mechanism of Action
7.9.3.1.3. Clinical Development Status
7.9.3.1.4. Key Clinical Trial Results
7.9.4. Recent Collaborations
 
7.10. Pfizer
7.10.1. Company Overview
7.10.2. Financial Performance
7.10.3. Pipeline Overview
7.10.3.1. BESPONSA®
7.10.3.1.1. Drug Overview
7.10.3.1.2. Mechanism of Action
7.10.3.1.3. Approval History
7.10.3.1.4. Clinical Development Status
7.10.3.1.5. Key Clinical Trial Results
7.10.3.2. MYLOTARG™
7.10.3.2.1. Drug Overview
7.10.3.2.2. Mechanism of Action
7.10.3.2.3. Approval History
7.10.3.2.4. Clinical Development Status
7.10.3.2.5. Key Clinical Trial Results
7.10.4. Recent Collaborations
 
7.11. Roche / Genentech
7.11.1. Company Overview
7.11.2. Financial Performance:
7.11.3. Pipeline Overview
7.11.3.1. KADCYLA®
7.11.3.1.1. Drug Overview
7.11.3.1.2. Mechanism of Action
7.11.3.1.3. Cost, Dosage and Reimbursement 
7.11.3.1.4. Approval History
7.11.3.1.5. KADCYLA Sales, 2013-Q1 2017
7.11.3.1.6. Clinical Development Status
7.11.3.1.7. Key Clinical Trial Results
7.11.3.2. RG-7596
7.11.3.2.1. Drug Overview
7.11.3.2.2. Mechanism of Action
7.11.3.2.3. Clinical Development
7.11.3.2.4. Key Clinical Trial Results
7.11.4. Recent Collaborations
 
7.12. Sanofi
7.12.1. Company Overview
7.12.2. Financial Performance-
7.12.3. Pipeline Overview
7.12.3.1. SAR-566658 / huDS6-DM4
7.12.3.1.1. Drug Overview
7.12.3.1.2. Mechanism of Action
7.12.3.1.3. Clinical Development
7.12.3.1.4. Key Clinical Results
7.12.4. Recent Collaborations
 
7.13. Seattle Genetics
7.13.1. Company Overview
7.13.2. Financial Performance
7.13.3. Pipeline Overview
7.13.3.1. ADCETRIS®
7.13.3.1.1. Drug Overview
7.13.4. Mechanism of Action
7.13.4.1.1. Cost, Dosage and Reimbursement 
7.13.4.1.2. Approval History
7.13.4.1.3. ADCETRIS® Sales, 2011-H1 2017
7.13.4.1.4. Clinical Development
7.13.4.1.5. Key Clinical Trial Results
7.13.4.2. SGN-CD19A
7.13.4.2.1. Drug Overview
7.13.4.2.2. Mechanism of Action
7.13.4.2.3. Clinical Development
7.13.4.2.4. Key Clinical Trial Results
7.13.5. Recent Collaborations
 
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Chapter Overview
8.2. Partnership Models
8.3. ADCs: List of Partnerships
8.4. ADCs: Analysis of Partnerships
8.4.1 Analysis by Year of Partnerships
8.4.2. Analysis by Type of Partnerships
8.4.3. Most Active Companies: Analysis by Number of Partnerships
 
9. VENTURE FUNDING
9.1. Chapter Overview
9.2. Types of Funding
9.3. ADCs: Funding Instances
9.4. ADCs: Analysis of Funding
9.4.1. Analysis by Number of Funding Instances
9.4.2. Analysis by Amount Invested
9.4.3. Analysis by Type of Funding
9.4.4. Most Active Companies: Analysis by Number of Funding Instances
9.4.5. Most Active Investors: Analysis by Number of Funding Instances
 
10. ACADEMIC GRANTS
10.1. Chapter Overview
10.2. ADCs: List of Recent Academic Grants
10.3. ADCs: Analysis of Grants
10.3.1. Analysis by Number of Grants
10.3.2. Analysis by Amount of Grant
10.3.3. Analysis by Type of Grant
10.3.4. Analysis by Leading Organization
10.3.5. Analysis by Therapeutic Area
10.3.6. Analysis by Therapeutic Target
 
11. COMBINATION THERAPIES
11.1. Chapter Overview
11.2. Combination Therapy: History of Development
11.3. FDA-approved Combination Therapies in Oncology
11.4. Combination Therapies: FDA Guidelines
11.4.1. Combinations of Marketed Drugs
11.4.2. Combinations of Marketed Drugs or Biologics with New Molecular Entities
11.4.3. Combinations of New Molecular Entities 
11.5. Combination Therapies: ADCs
11.5.1. ADCs Clinical Studies: Distribution by Therapy Type
11.5.2. ADCs Combination Therapy Clinical Studies
11.5.3. ADCs: Analysis of Combinations
11.5.2.1. Analysis by Highest Phase of Development
11.5.2.2. Analysis by Current Trial Status
11.5.2.3. Analysis by Type of Combination Therapy
11.5.2.4. Analysis by Indication and Combination
 
12. NOVEL CONJUGATION TECHNOLOGY PLATFORMS
12.1. Chapter Overview
12.2. First Generation ADC Technologies
12.3. Second Generation ADC Technologies
12.3.1. Cysteine and Selenocysteine Engineering
12.3.2. Unnatural Amino Acid Engineering
12.3.3. Amino-Terminal Engineered Serine
12.4. Third Generation ADC Technologies
12.4.1. Enzyme-Assisted Ligation Approaches
12.4.2. Glycan Remodeling Approaches
12.4.3. Ligation at Fab Nucleotide-Binding Site
12.4.4. Cysteine Rebridging
12.4.5. Avoiding or Limiting Retro-Michael Drug Deconjugation
12.5. Evolutionary Analysis
 
13. ASSESMENT OF NON-CLINICAL DATA, FIRST IN HUMAN DOSING
13.1. Chapter Overview
13.2. ADCs and Non-Clinical Studies
13.3. ICH S9 Guidelines
13.4. Investigational New Drug (IND)-Enabling Study Designs
13.4.1. Example Case: KADCYLA®
13.5. Toxicities in Animal Models
13.6. Prediction of Maximum Tolerated Dosage (MTD) in Humans
13.7. Other Key Considerations for Study Design
 
14. PATENT ANALYSIS
14.1. Chapter Overview
14.2. Scope and Methodology
14.3. ADC Patents: Distribution by Publication Year
14.4. ADC Patents: Distribution by Geographical Location
14.5. ADC Patents: Distribution by CPC Classifications
14.6. ADC Patents: Emerging Areas
14.7. ADC Patents: Leading Players
14.8. ADC Patents: Benchmarking Analysis
14.8.1. Benchmarking Analysis: Patent Characteristics
14.8.2. Benchmarking Analysis: Geographical Distribution
14.9. ADC Patents: Emerging Players
14.10. ADC Patents: Patent Valuation
14.11. ADC Patents: Leading Citations
 
15. CASE STUDY: ADC MANUFACTURING
15.1. Chapter Overview
15.2. Key Steps in ADC Manufacturing
15.3. Challenges Associated with ADC Manufacturing
15.4. Limitations of In-House Manufacturing
15.5. Growing Demand for Contract Manufacturing
15.6. Emergence of Start-Ups Offering Contract Services
15.7. Investments in ADC Manufacturing Capability Expansions
15.8. Collaborations Established for ADC Manufacturing
15.9. CMOs with Linker Manufacturing Capabilities
15.10. CMOs with HPAPI / Cytotoxic Payload Manufacturing Capabilities
15.11. CMOs with Conjugation Capabilities
15.12. ADC One Stop Shops
 
16. MARKET FORECAST AND OPPORTUNITY ANALYSIS
16.1. Chapter Overview
16.2. Scope and Limitations
16.3. Forecast Methodology
16.4. Overall ADCs Therapeutics Market
16.4.1. ADCs Therapeutics Market: Distribution by Therapeutic Area
16.4.2. ADCs Therapeutics Market: Distribution by Technology Providers
16.4.3. ADCs Therapeutics Market: Distribution by Type of Linker
16.4.4. ADCs Therapeutics Market: Distribution by Type of Payload
16.5. ADCs Therapeutics Market: Individual Drug Forecasts
16.5.1. ADCETRIS®
16.5.1.1. Target Patient Population
16.5.1.2. Sales Forecast
16.5.2. KADCYLA®
16.5.2.1. Target Patient Population
16.5.2.2. Sales Forecast
16.5.3. MYLOTARG™
16.5.3.1. Target Patient Population
16.5.3.2. Sales Forecast
16.5.4. BESPONSA®
16.5.4.1. Target Patient Population
16.5.4.2. Sales Forecast
16.5.5. IMMU-132
16.5.5.1. Target Patient Population
16.5.5.2. Sales Forecast
16.5.6. Rova-T
16.5.6.1. Target Patient Population
16.5.6.2. Sales Forecast
16.5.7. IMGN853
16.5.7.1. Target Patient Population
16.5.7.2. Sales Forecast
16.5.8. RG7596
16.5.8.1. Target Patient Population
16.5.8.2. Sales Forecast
16.5.9. PSMA ADC
16.5.9.1. Target Patient Population
16.5.9.2. Sales Forecast
16.5.10. BAY 94-9343
16.5.10.1. Target Patient Population
16.5.10.2. Sales Forecast
16.5.11. SAR3419
16.5.11.1. Target Patient Population
16.5.11.2. Sales Forecast
16.5.12. IMMU-130
16.5.12.1. Target Patient Population
16.5.12.2. Sales Forecast
16.5.13. AGS 16M8F / AGS 16C3F
16.5.13.1. Target Patient Population
16.5.13.2. Sales Forecast
16.5.14. CDX-011
16.5.14.1. Target Patient Population
16.5.14.2. Sales Forecast
16.5.15. SAR566658
16.5.15.1. Target Patient Population
16.5.15.2. Sales Forecast
16.5.16. ABT-414
16.5.16.1. Target Patient Population
16.5.16.2. Sales Forecast
16.5.17. SGN-CD19A
16.5.17.1. Target Patient Population
16.5.17.2. Sales Forecast
16.5.18. IMGN529
16.5.18.1. Target Patient Population
16.5.18.2. Sales Forecast
16.5.19. ASG-22ME
16.5.19.1. Target Patient Population
16.5.19.2. Sales Forecast
 
17. SWOT ANALYSIS
17.1. Chapter Overview
17.2. Strengths
17.3. Weaknesses
17.4. Opportunities
17.5. Threats
 
18. CONCLUSION
18.1. The Recent Approval of MYLOTARG™ and BESPONSA® has Renewed the Interest in ADCs
18.2. In Addition to Established Players, Start-ups, Backed by Venture Capital Investors, are Significantly Driving Innovation in this Domain
18.3. With Multiple Late-phase Candidates, the ADCs Space is Characterized by a Robust and Promising Pipeline
18.4. More Potent Warheads, Novel Targets and Innovative Conjugation Platforms have Emerged as Potential Areas of Research
18.5. Several Stakeholders have Entered into Strategic Alliances to Further R&D Efforts in this Domain
18.6. CMOs Continue to a Play Significant Role in Driving the Industry Forward
18.7. Post the Approval and Launch of Multiple Late-phase Product Candidates, the Market is Expected to Grow at a Rapid Pace
 
19. INTERVIEW TRANSCRIPTS
19.1. Chapter Overview
19.2. Alan Burnett, Professor, School of Medicine, James Cardiff University
19.3. Sasha Koniev, Chief Executive Officer, Syndivia
19.4.  Anthony DeBoer, Director, Business Development, Synaffix
19.4. Mark Wright, Site Head, Grangemouth, Piramal Healthcare 
19.6. Christian Bailly, Head of CDMO, Pierre Fabre
19.7. Anonymous, Director, Business Development, Leading CMO 
19.8. John Burt, Chief Executive Officer, Abzena
19.9. Christian Rohlff, Founder and CEO, Oxford BioTherapeutics 
19.10. Laurent Ducry, ADC R&D, Lonza
19.11. Stacy McDonald, Group Product Manager and Jennifer L. Mitcham, Director, Business Development, Catalent Pharma Solutions
19.12. Aldo Braca, Chief Executive Officer, BSP Pharmaceuticals
19.13. Anonymous, Chief Executive Officer, Leading CMO 

 

 
20. APPENDIX 1: TABULATED DATA
 
21. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
 
 

 

 
Figure 3.1 Cancer Treatments: Timeline
 
Figure 3.2 Cancer Treatments: Type of Surgeries
 
Figure 3.3 Cancer Treatments: Type of Radiation Therapies
 
Figure 3.3 Cancer Treatments: Type of Chemotherapies
 
Figure 3.4 Components of ADC
 
Figure 3.5 Comparative Analysis of Pharmacokinetic Properties of ADCs: Dosage, Regimen, Cmax and T1/2
 
Figure 4.1 ADCs Clinical Pipeline: Distribution by Phase of Development
 
Figure 4.2 ADCs Clinical Pipeline: Distribution by Indication
 
Figure 4.3 ADCs Clinical Pipeline: Distribution by Target
 
Figure 4.4 ADCs Clinical Pipeline: Distribution by Type of Linker
 
Figure 4.5 ADCs Clinical Pipeline: Distribution by Type of Warhead
 
Figure 4.6 ADCs Clinical Pipeline: Distribution by Technology Providers
 
Figure 4.7 ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
 
Figure 4.8 ADCs Preclinical Pipeline: Distribution by Key Players
 
Figure 5.1 ADCETRIS®: Mapping Prominent Researchers
 
Figure 5.2 KADCYLA®: Mapping Prominent Researchers
 
Figure 5.3 MYLOTARG™: Mapping Prominent Researchers
 
Figure 5.4 Other ADCs: Mapping Prominent Researchers
 
Figure 5.5 ADCs: Prominent Key Opinion Leaders
 
Figure 6.1 Leukemia: Classification
 
Figure 6.2 Leukemia: Global Epidemiological Distribution
 
Figure 6.3 Lymphoma: Global Epidemiological Distribution
 
Figure 6.4 Multiple Myeloma: Global Epidemiological Distribution
 
Figure 6.5 Melanoma: Global Epidemiological Distribution
 
Figure 6.6 Lung Cancer: Classification
 
Figure 6.7 Lung Cancer: Global Epidemiological Distribution
 
Figure 6.8 Bladder Cancer: Global Epidemiological Distribution
 
Figure 6.9 Kidney Cancer: Global Epidemiological Distribution
 
Figure 6.10 Ovarian Cancer: Global Epidemiological Distribution
 
Figure 6.11 Breast Cancer: Global Epidemiological Distribution
 
Figure 6.12 Colorectal Cancer: Global Epidemiological Distribution
 
Figure 6.13 Prostate Cancer: Global Epidemiological Distribution
 
Figure 7.1 AbbVie: Annual Revenues, 2012-H1 2017 (USD Billion)
 
Figure 7.2 ABT-414: Registered Clinical Trials
 
Figure 7.3 Astellas Pharma: Annual Revenues, 2012-2017 (JPY Billion)
 
Figure 7.4 ASG-22ME: Registered Clinical Trials, 2017
 
Figure 7.5 ASG-22ME: Key Clinical Trial Results, June 2017
 
Figure 7.6 ASG 16M8F: Registered Clinical Trials, 2017
 
Figure 7.7 Bayer Healthcare: Annual Revenues, 2012-H1 2017 (EUR Billion)
 
Figure 7.8 BAY 94-9343: Registered Clinical Trials
 
Figure 7.9 Biotest Pharmaceuticals: Annual Revenues, 2012-2016 (EUR Million)
 
Figure 7.10 BT-062: Registered Clinical Trials
 
Figure 7.11 Celldex Therapeutics: Annual Revenues, 2012-H1 2017 (USD Million)
 
Figure 7.12 CDX-011: Registered Clinical Trials
 
Figure 7.13 ImmunoGen: Annual Revenues, 2012-H1 2017 (USD Million)
 
Figure 7.14 IMGN853: Registered Clinical Trials
 
Figure 7.15 IMGN853: Treatment-Related Adverse Events for Solid Tumors
 
Figure 7.16 IMGN853: Treatment-Related Adverse Events for Platinum Related Diseases
 
Figure 7.17 IMGN529: Registered Clinical Trials
 
Figure 7.18 Immunomedics: Annual Revenues, 2013-2017 (USD Million)
 
Figure 7.19 IMMU-130: Registered Clinical Trials
 
Figure 7.20 Progenics Pharmaceuticals: Annual Revenues, 2012-H1 2017 (USD Million)
 
Figure 7.21 PSMA ADC: Registered Clinical Trials
 
Figure 7.22 Pfizer: Annual Revenues, 2012-H1 2017 (USD Billion)
 
Figure 7.23 BESPONSA®: Registered Clinical Trials
 
Figure 7.24 MYLOTARG™: Mechanism of Action
 
Figure 7.25 Roche: Annual Revenues, 2012-H1 2017 (USD Billion)
 
Figure 7.26 KADCYLA®: Registered Clinical Trials
 
Figure 7.27 KADCYLA®: Annual Sales, 2013-Q1 2017 (CHF Million)
 
Figure 7.28 RG-7596: Registered Clinical Trials
 
Figure 7.29 Sanofi: Key Therapeutic Focus Areas
 
Figure 7.30 Sanofi: Annual Revenues, 2012-2016 (USD Billion)
 
Figure 7.31 SAR-566658: Registered Clinical Trials
 
Figure 7.32 Seattle Genetics: Annual Revenues, 2012-H1 2017 (EUR Millions)
 
Figure 7.33 ADCETRIS®: Registered Clinical Trials
 
Figure 7.34 ADCETRIS®: Annual Sales, 2012-H1 2017 (USD Million)
 
Figure 7.35 SGN-CD19A: Registered Clinical Trials
 
Figure 7.36 SGN-CD19A: Key Clinical Trial Results, December 2015
 
Figure 8.1 ADC Partnerships: Cumulative Year-wise Trend (2007-2017)
 
Figure 8.2 ADC Partnerships: Distribution by Most Active Players
 
Figure 8.3 ADC Partnerships: Distribution by Type of Collaboration
 
Figure 8.4 ADC Partnerships: Distribution by Year and Type of Collaboration
 
Figure 9.1 ADCs Investments: Cumulative Number of Funding Instances, Pre-2007-2017
 
Figure 9.2 ADCs Investments: Cumulative Amount Invested, Pre-2007-2017 (USD Million)
 
Figure 9.3 ADCs Investments: Distribution of Number of Funding Instance by Type, 2007-2017
 
Figure 9.4 ADCs Investments: Distribution of Funding Amount by Type, 2007-2017 (USD Million)
 
Figure 9.5 ADCs Investments: Distribution by Type of Funding and Amount Invested (USD Million)
 
Figure 9.6 ADCs Investments: Distribution by Leading Players
 
Figure 9.7 ADC Investments: Most Active Investors
 
Figure 10.1 ADCs Grants: Distribution by Number of Grants (2011-2017)
 
Figure 10.2 ADCs Grants: Year-wise Distribution by Grant Amount (USD Million)
 
Figure 10.3 ADCs Grants: Distribution by Grant Type
 
Figure 10.4 ADCs Grants: Distribution by States in the US
 
Figure 10.5 ADC Grants: Distribution by Leading Organizations
 
Figure 10.6 ADCs Grants: Distribution by Therapeutic Area
 
Figure 10.7 ADC Grants: Distribution by Therapeutic Target
 
Figure 11.1 ADCs Clinical Studies: Distribution by Type of Therapy Evaluation
 
Figure 11.2 ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
 
Figure 11.3 ADCs Combination Therapy Clinical Studies: Distribution by Trial Status
 
Figure 11.4 ADCs Combination Therapy Clinical Studies: Distribution by Trial Date and Type of Combination
 
Figure 11.5 ADCs Combination Therapy Clinical Studies: Distribution by Indications and Type of Combination
 
Figure 12.1 ADC Platforms: Technological Evolution
 
Figure 12.2 ADC Conjugation Platforms: Technology Landscape
 
Figure 13.1 First in Human Dose Calculation: Dose Escalation using BSA Conversion
 
Figure 13.2 Relationship between DLTs and ADC Warhead
 
Figure 13.3 Maximum Tolerated Dose (MTD): Relationship between Drug to Antibody Ratio and (Highest Non-Severely Toxic Dose) HNSTD
 
Figure 14.1 ADC Patents: Distribution by Type of Patent
 
Figure 14.2 ADC Patents: Distribution by Publication Year
 
Figure 14.3 ADC Patents: Year-wise Regional Distribution
 
Figure 14.4 ADC Patents: Cumulative Distribution by CPC Classification Symbol
 
Figure 14.5 ADC Patents: Emerging Areas
 
Figure 14.6 ADC Patents: Distribution by Leading Assignees
 
Figure 14.7 ADC Patents: Geographical Distribution of Leading Players
 
Figure 14.8 ADC Patents: Benchmarking by Patent Characteristics
 
Figure 14.9 ADC Patents: Benchmarking by Geographical Distribution
 
Figure 14.10 ADC Patents: Benchmarking by International Patents
 
Figure 14.11 ADC Patents: Emerging Players (2013-2017)
 
Figure 14.12 ADC Patents: Age of Patent
 
Figure 14.13 ADC Patents: Patent Valuation
 
Figure 16.1 Overall ADCs Therapeutics Market, 2017-2030: Base Scenario (USD Billion)
 
Figure 16.2 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Therapeutic Area
 
Figure 16.3 ADC Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Technology Providers
 
Figure 16.4 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Type of Linker
 
Figure 16.5 ADCs Therapeutics Market (USD Billion), 2017, 2025 and 2030 (Base Scenario): Distribution by Type of Payload
 
Figure 16.6 ADCETRIS® Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.7 KADCYLA® Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.8 MYLOTARG™ Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.9 BESPONSA® Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.10 IMMU-132 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.11 Rova-T Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.12 IMGN853 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.13 RG7596 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.14 PSMA ADC Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.15 BAY 94-9343 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.16 SAR3419 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.17 IMMU-130 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.18 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.19 CDX-011 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.20 SAR56668 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.21 ABT-414 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.22 SGN-CD19A Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.23 IMGN529 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 16.24 ASG-22ME Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Figure 17.1 ADCs SWOT Analysis: Overview
 
Figure 17.2 ADCs SWOT Analysis: Strengths
 
Figure 17.3 ADCs SWOT Analysis: Weaknesses
 
Figure 17.4 ADCs SWOT Analysis: Opportunities
 
Figure 17.5 ADCs SWOT Analysis: Threats
 
Figure 19.1 Overall ADCs Therapeutic Market: Conservative, Base and Optimistic Scenario, 2017, 2025 and 2030 (USD Billion)
 
 
Table 3.1 FDA Approved Antibody Based Therapeutics for Cancer
 
Table 3.2 Commonly Used Cytotoxins for ADC Therapeutics
 
Table 3.3 Occupational Exposure Limit (OEL): Bands
 
Table 3.4 Comparison of Pharmacokinetic Properties: ADCs, Small Molecules and Monoclonal Antibodies
 
Table 4.1 ADCs: Clinical Pipeline
 
Table 4.2 ADCs: Clinical Pipeline (Linker and Payloads)
 
Table 4.3 ADCs: Discontinued Drugs
 
Table 4.4 ADCs: Preclinical Pipeline
 
Table 5.1 ADCs: List of KOLs
 
Table 6.1 Comparison of Hodgkin’s and Non-Hodgkin’s Lymphoma
 
Table 6.2 Leukemia: List of Marketed Targeted Therapeutics
 
Table 6.3 Lymphoma: List of Marketed Targeted Therapeutics
 
Table 6.4 ADCs for Leukemia and Lymphoma
 
Table 6.5 Multiple Myeloma: List of Marketed Targeted Therapeutics 
 
Table 6.6 ADCs for Multiple Myeloma
 
Table 6.7 Melanoma: List of Marketed Targeted Therapeutics
 
Table 6.8 ADCs for Metastatic Melanoma
 
Table 6.9 Lung Cancer: List of Marketed Targeted Therapeutics
 
Table 6.10 ADCs for Lung Cancer
 
Table 6.11 ADCs for Bladder Cancer
 
Table 6.12 Renal Cell Carcinoma: List of Marketed Targeted Therapeutics
 
Table 6.13 ADCs for Kidney Cancer
 
Table 6.14 ADCs for Ovarian Cancer
 
Table 6.15 Breast Cancer: List of Marketed Targeted Therapeutics
 
Table 6.16 ADCs for Breast Cancer
 
Table 6.17 ADCs for Glioblastoma
 
Table 6.18 Colorectal Cancer: List of Marketed Targeted Therapeutics
 
Table 6.19 ADCs for Colorectal Cancer
 
Table 6.20 Prostate Cancer: List of Marketed Targeted Therapeutics
 
Table 6.21 ADCs for Prostate Cancer
 
Table 7.1 AbbVie: ADCs Pipeline
 
Table 7.2 ABT-414: Registered Clinical Trials
 
Table 7.3 Astellas Pharma: ADCs Pipeline
 
Table 7.4 ASG-22ME: Registered Clinical Trials
 
Table 7.5 ASG 16M8F: Registered Clinical Trials
 
Table 7.6 Bayer Healthcare: ADCs Pipeline
 
Table 7.7 BAY 94-9343: Registered Clinical Trials
 
Table 7.8 Biotest Pharmaceuticals: ADCs Pipeline
 
Table 7.9 BT-062: Registered Clinical Trials
 
Table 7.10 Celldex Therapeutics: ADCs Pipeline
 
Table 7.11 CDX-011: Registered Clinical Trials
 
Table 7.12 ImmunoGen: ADCs Pipeline
 
Table 7.13 IMGN853: Registered Clinical Trials
 
Table 7.14 IMGN529: Registered Clinical Trials
 
Table 7.15 Immunomedics: ADCs Pipeline
 
Table 7.16 IMMU-130: Registered Clinical Trials
 
Table 7.17 IMMU-130: Registered Clinical Trials
 
Table 7.18 Progenics Pharmaceuticals: ADCs Pipeline
 
Table 7.19 PSMA ADC: Registered Clinical Trials
 
Table 7.20 Pfizer: ADCs Pipeline
 
Table 7.21 BESPONSA®: Registered Clinical Trials
 
Table 7.22 MYLOTARG™:  Registered Clinical Trials
 
Table 7.23 Roche: ADCs Pipeline
 
Table 7.24 KADCYLA®: Ongoing Clinical Trials
 
Table 7.25 RG-7596: Registered Clinical Trials
 
Table 7.26 ASG-22ME: Registered Clinical Trials
 
Table 7.27 Seattle Genetics: ADCs Pipeline
 
Table 7.28 ADCETRISR®: Registered Clinical Trials
 
Table 7.29 SGN-CD19A: Registered Clinical Trials
 
Table 8.1 ADCs: List of Partnerships, 2005-2017
 
Table 9.1 ADCs: List of Funding Instances, Pre-2007-2017
 
Table 9.2 ADCs: Types of Funding Instances, Pre- 2007-2017
 
Table 10.1 ADCs: List of Academic Grants, 2011-2017
 
Table 11.1 FDA Approved Combination Therapies in Oncology, 2001-2015
 
Table 11.2 ADCs Combination Therapy Clinical Studies: Key Indications
 
Table 12.1 Second Generation ADC Technologies: Cysteine and Selenocysteine Engineering
 
Table 12.2 Second Generation ADC Technologies: Unnatural Amino Acid Engineering
 
Table 12.3 Second Generation ADC Technologies: Amino-terminal Engineered Serine
 
Table 12.4 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
 
Table 12.5 Third Generation ADC Technologies: Glycan Remodeling Approaches
 
Table 12.6 Third Generation ADC Technologies: Enzyme-Assisted Ligation Approaches
 
Table 12.7 Third Generation ADC Technologies: Cysteine Rebridging
 
Table 12.8 Third Generation ADC Technologies: Avoiding or Limiting Retro-Michael Drug Deconjugation
 
Table 13.1 ADCs Non-Clinical Studies: Safety Packages Required
 
Table 13.2 Single Dose Study of KADCYLA® in Cynomolgus Monkey
 
Table 13.3 ADCs: Dose Limiting Toxicities in Clinical Studies
 
Table 14.1 ADCs Patents: CPC Symbol Definitions
 
Table 14.2 ADCs Patents: Most Popular CPC Symbols
 
Table 15.1 Contract Manufacturers and Their Capabilities in ADC Manufacturing
 
Table 15.2 Contract Manufacturers for ADCs: Distribution by Geography
 
Table 15.3 Full Service Provider CMOs for ADC Manufacturing: Distribution by Geography
 
Table 16.1 ADCs Therapeutics: Expected Launch Years
 
Table 16.2 ADCETRIS®: Target Patient Population
 
Table 16.3 KADCYLA®: Target Patient Population
 
Table 16.4 MYLOTARG™: Target Patient Population
 
Table 16.5 BESPONSA®: Target Patient Population
 
Table 16.6 IMMU-132: Target Patient Population
 
Table 16.7 Rova-T: Target Patient Population
 
Table 16.8 IMGN853: Target Patient Population
 
Table 16.9 RG7596: Target Patient Population
 
Table 16.10 PSMA ADC: Target Patient Population
 
Table 16.11 BAY 94-9343: Target Patient Population
 
Table 16.12 SAR3419: Target Patient Population
 
Table 16.13 IMMU-130: Target Patient Population
 
Table 16.14 AGS 16M8F / AGS 16C3F: Target Patient Population
 
Table 16.15 CDX-011: Target Patient Population
 
Table 16.16 SAR566658: Target Patient Population
 
Table 16.17 ABT-414: Target Patient Population
 
Table 16.18 SGN-CD19A: Target Patient Population
 
Table 16.19 IMGN529: Target Patient Population
 
Table 16.20 ASG-22ME: Target Patient Population
 
Table 20.1 ADCs Clinical Pipeline: Distribution by Phases of Development
 
Table 20.2 ADCs Clinical Pipeline: Distribution by Indication
 
Table 20.3 ADCs Clinical Pipeline: Distribution by Target
 
Table 20.4 ADCs Clinical Pipeline: Distribution by Types of Linker
 
Table 20.5 ADCs Clinical Pipeline: Distribution by Types of Warhead
 
Table 20.6 ADCs Clinical Pipeline: Distribution by Technology Providers
 
Table 20.7 ADCs Clinical Pipeline: Four-Dimensional Grid Analysis
 
Table 20.8 ADCs Preclinical Pipeline: Distribution by Key Players
 
Table 20.9 AbbVie: Revenue, 2012 – H1 2017 (USD Billion)
 
Table 20.10 ABT-414: Registered Clinical Trials
 
Table 20.11 Astellas Pharma: Revenue, 2012 –2017 (JPY Billion)
 
Table 20.12 ASG-22ME: Registered Clinical Trials
 
Table 20.13 ASG 16M8F: Registered Clinical Trials
 
Table 20.14 Bayer Healthcare: Revenues, 2012 – H1 2017 (EUR Billion)
 
Table 20.15 BAY 94-9343: Registered Clinical Trials
 
Table 20.16 Biotest Pharmaceuticals: Revenue, 2012-2016 (EUR Million)
 
Table 20.17 BT-062: Registered Clinical Trials
 
Table 20.18 Celldex Therapeutics: Revenue, 2012 – H1 2017 (USD Million)
 
Table 20.19 CDX-011: Registered Clinical Trials
 
Table 20.20 ImmunoGen: Revenues, 2012 – H1 2017 (USD Million)
 
Table 20.21 IMGN853: Registered Clinical Trials
 
Table 20.22 IMGN529: Registered Clinical Trials
 
Table 20.23 SAR3419: Registered Clinical Trials
 
Table 20.24 Immunomedics: Revenues 2013-2017 (USD Million)
 
Table 20.25 IMMU-130: Registered Clinical Trials
 
Table 20.26 IMMU-132: Registered Clinical Trials
 
Table 20.27 Progenics Pharmaceuticals: Revenue, 2012 – H1 2017 (USD Million)
 
Table 20.28 PSMA ADC: Registered Clinical Trials
 
Table 20.29 Pfizer: Revenues, 2012 – H1 2017 (USD Billion)
 
Table 20.30 BESPONSA®: Registered Clinical Trials
 
Table 20.31 MYLOTARG™: Registered clinical trials, 2017
 
Table 20.32 Roche: Revenues, 2012 – H1 2017 (USD Billion)
 
Table 20.33 KADCYLA®: Registered Clinical Trials
 
Table 20.34 KADCYLA® Sales: 2013- Q1 2017 (CHF Million)
 
Table 20.35 RG-7596: Registered Clinical Trials
 
Table 20.36 Sanofi: Revenues, 2012-2016 (USD Billion)
 
Table 20.37 SAR-566658: Registered Clinical Trials
 
Table 20.38 Seattle Genetics: Revenue 2012-H1 2017 (EUR Million)
 
Table 20.39 ADCETRIS®: Registered Clinical Trials
 
Table 20.40 ADCETRIS® Sales: 2012- H1 2017 (USD Million)
 
Table 20.41 SGN-CD19A: Registered Clinical Trials
 
Table 20.42 ADCs Partnerships Cumulative Trend, 2005-2017
 
Table 20.43 ADCs Partnerships: Key Players
 
Table 20.44 ADCs Partnerships: Distribution by Types
 
Table 20.45 ADCs Partnerships: Distribution by Year Wise Trend
 
Table 20.46 ADCs Investments: Cumulative Number of Funding Instances, Pre 2007 – 2017
 
Table 20.47 ADCs Investments: Cumulative Amount Invested, 2007- 2017 (USD Million)
 
Table 20.48 ADCs Investments: Distribution of Number of Funding Instance by Type, 2007 – 2017
 
Table 20.49 ADCs Investments: Distribution of Funding Amount by Funding Type, 2007 – 2017 (USD Million)
 
Table 20.50 ADCs Investments: Distribution by Leading Players
 
Table 20.51 ADCs Investments: Distribution by Leading Investors
 
Table 20.52 Academic Grant Analysis: Distribution of Number of Grants
 
Table 20.53 Academic Grant Analysis: Distribution by Grant Type
 
Table 20.54 Academic Grant Analysis: Distribution by Leading Organizations
 
Table 20.55 Academic Grant Analysis: Cumulative Distribution by Therapeutic Area
 
Table 20.56 Academic Grant Analysis: Distribution by Therapeutic Target
 
Table 20.57 ADCs Clinical Studies: Distribution by Type of Therapy Evaluation
 
Table 20.58 ADCs Combination Therapy Clinical Studies: Distribution by Highest Phase of Development
 
Table 20.59 ADCs Combination Therapy Clinical Studies: Distribution by Trial Status
 
Table 20.60 ADC Patents: Distribution by Type of Patent 
 
Table 20.61 ADCs Patents: Distribution by Publication Year
 
Table 20.62 ADCs Patents: Year-wise Regional Distribution
 
Table 20.63 ADCs Patents: Distribution by Leading Assignees
 
Table 20.64 ADCs Patents: Benchmarking by Patent Characteristics  
 
Table 20.65 ADCs Patents: Benchmarking by International Patents 
 
Table 20.66     ADC Patents: Age of Patent
 
Table 20.67 ADCs Patents: Patent Valuation
 
Table 20.68 Overall ADCs Therapeutics Market, 2017-2030: Optimistic Scenario (USD Billion)
 
Table 20.69 Overall ADCs Therapeutics Market, 2017-2030: Base Scenario (USD Billion)
 
Table 20.70 Overall ADCs Therapeutics Market, 2017-2030: Conservative Scenario (USD Billion)
 
Table 20.71 Overall ADCs Therapeutics Market (USD Million), Base Scenario) 
 
Table 20.72 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Technology Providers
 
Table 20.73 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Technology Providers
 
Table 20.74 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Technology Providers
 
Table 20.75 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Type of Linker
 
Table 20.76 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Type of Linker
 
Table 20.77 ADCs Therapeutics Market (USD Billion), 2030 (Base Scenario): Distribution by Type of Linker
 
Table 20.78 ADCs Therapeutics Market (USD Billion), 2017 (Base Scenario): Distribution by Type of Payload
 
Table 20.79 ADCs Therapeutics Market (USD Billion), 2025 (Base Scenario): Distribution by Type of Payload
 
Table 20.80 ADCs Therapeutics Market (USD Billion), 2030 (Base Scenario): Distribution by Type of Payload
 
Table 20.81 ADCETRIS® Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.82 ADCETRIS® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.83 ADCETRIS® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.84 KADCYLA® Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.85 KADCYLA® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.86 KADCYLA® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.87 MYLOTARG™ Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.88 MYLOTARG™ Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.89 MYLOTARG™ Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.90 BESPONSA® Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.91 BESPONSA® Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.92 BESPONSA® Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.93 IMMU-132 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.94 IMMU-132 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.95 IMMU-132 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.96 Rova-T Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.97 Rova-T Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.98 Rova-T Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.99 IMGN853 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.100 IMGN853 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.101 IMGN853 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.102 RG7596 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.103 RG7596 Sales Forecast (Till 2030): Conservative Scenario (USD Million
 
Table 20.104 RG7596 Sales Forecast (Till 2030): Optimistic Scenario (USD Million
 
Table 20.105 PSMA ADC Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.106 PSMA ADC Sales Forecast (Till 2030):  Base Scenario (USD Million)
 
Table 20.107 PSMA ADC Sales Forecast (Till 2030):  Conservative Scenario (USD Million)
 
Table 20.108 BAY 94-9343 Sales Forecast (Till 2030): Optimistic Scenario (USD Million
 
Table 20.109 BAY 94-9343 Sales Forecast (Till 2030): Base Scenario (USD Million
 
Table 20.110 BAY 94-9343 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.110 SAR3419 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.111 SAR3419 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.112 SAR3419 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.113 IMMU-130 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.114 IMMU-130 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.115 IMMU-130 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.116 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.117 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.118 AGS 16M8F / AGS 16C3F Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.119 CDX-011 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.120 CDX-011 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.121 CDX-011 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.122 SAR56668 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.123 SAR56668 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.124 SAR56668 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.125 ABT-414 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.126 ABT-414 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.127 ABT-414 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.128 SGN-CD19A Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.129 SGN-CD19A Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.130 SGN-CD19A Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.131 IMGN529 Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.132 IMGN529 Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.133 IMGN529 Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.134 ASG-22ME Sales Forecast (Till 2030): Base Scenario (USD Million)
 
Table 20.135 ASG-22ME Sales Forecast (Till 2030): Conservative Scenario (USD Million)
 
Table 20.136 ASG-22ME Sales Forecast (Till 2030): Optimistic Scenario (USD Million)
 
Table 20.137 Overall ADCs Therapeutic Market: Conservative, Base and Optimistic Scenario, 2017, 2025 and 2030 (USD Billion) 
 

The following companies and organizations have been mentioned in the report:

 

  1. 3P Biopharmaceuticals
  2. 3SBio
  3. 5AM Ventures
  4. Aarhus University Hospital
  5. Abbott
  6. AbbVie
  7. AbbVie Contract Manufacturing
  8. AbGenomics
  9. ABL Bio
  10. Abraxis BioScience
  11. Abzena
  12. Academic and Community Cancer Research United (ACCRU)
  13. Academisch Medisch Centrum (AMC)
  14. Academy of Military Medical Sciences
  15. ACES Pharma
  16. Acute Leukemia French Association (ALFA)
  17. ADC Biotechnology
  18. ADC Therapeutics
  19. Adimab
  20. Advanced Biotechnologies Venture Fund
  21. Advanced Proteome Therapeutics Corporation
  22. Advantage Capital
  23. Advent Venture Partners
  24. Affimed
  25. Affinity Life Sciences
  26. Agensys
  27. Aichi Cancer Center Hospital
  28. AIDS Malignancy Consortium (AMC)
  29. Ajinomoto Althea
  30. Alcami
  31. Alexandria Real Estate Equities
  32. Alligator Bioscience
  33. Allos Therapeutics
  34. Allozyne
  35. Ally Bridge Group
  36. Almac Group
  37. Alnylam Pharmaceuticals
  38. Alta Partners
  39. Alteogen
  40. Ambrx
  41. Amgen
  42. Amgen Ventures
  43. AMRI
  44. Angiex
  45. Apax Partners
  46. APO-T
  47. Apposite Capital
  48. Apricot Capital
  49. Aravis Ventures
  50. ARCH Venture Partners
  51. Array BioPharma
  52. Arrowpoint Partners
  53. Asan Medical Center
  54. Asana BioSciences
  55. Ash Stevens
  56. Aspyrian Therapeutics
  57. Astellas Pharma
  58. AstraZeneca
  59. Asymchem
  60. Auven Therapeutics
  61. Avacta
  62. Avicenna Oncology
  63. AvidBiologics
  64. BankInvest Group
  65. Barbara Ann Karmanos Cancer Institute
  66. Baxter BioPharma Solutions
  67. Bayer HealthCare
  68. Baylor College of Medicine
  69. BDC Capital
  70. Bear Stearns Health Innoventures
  71. Beatson West of Scotland Cancer Centre
  72. Beckman Research Institute of City of Hope
  73. BeiGene
  74. Beijing Cancer Hospital
  75. BerGenBio
  76. Bicycle Therapeutics
  77. BioAgilytix
  78. BioAtla
  79. Biogen
  80. BioGeneration Ventures
  81. BioMed Valley Discoveries
  82. BioOutsource
  83. Bio-Synthesis
  84. BioTechnique
  85. Biotecnol
  86. Biotest
  87. BlinkBio
  88. Boehringer Ingelheim
  89. Boehringer Ingelheim Venture Fund
  90. BOM Capital
  91. Bregua Corporation
  92. Brigham and Women's Hospital
  93. Bristol-Myers Squibb (BMS)
  94. Brown University
  95. BSP Pharmaceuticals
  96. BZL Biologics
  97. California Institute for Regenerative Medicine (CIRM)
  98. Cambrex
  99. Cancer Research UK Centre for Drug Development
  100. Cancer Treatment Centers of America
  101. Cantonal Hospital St. Gallen
  102. CARBOGEN AMCIS
  103. CARB-X
  104. Carnegie Kapitalforvaltning
  105. Cascade Investment Group
  106. Cascadian Therapeutics
  107. Casdin Capital
  108. Catalent
  109. Catalent Biologics
  110. Catapult Ventures
  111. CEL Healthcare Fund
  112. Celgene
  113. Celldex Therapeutics
  114. Cellectar Biosciences
  115. Cellerant Therapeutics
  116. Centocor Ortho Biotech Services
  117. Centre Hospitalier Lyon Sud
  118. Centre Oscar Lambret
  119. Centrose
  120. Cerbios-Pharma
  121. ChemCon
  122. ChemPartner
  123. Children's Hospital Los Angeles (CHLA)
  124. Children's Hospital of Philadelphia (CHOP)
  125. Children's Mercy Hospital
  126. Children's Oncology Group (COG)
  127. Chinese Academy of Medical Sciences
  128. Chiron Pharmaceuticals
  129. CHU de Limoges
  130. Chugai Pharmaceuticals
  131. Churchill Hospital
  132. CMC Biologics
  133. COARE Biotechnology
  134. Columbia University
  135. Comprehensive Cancer Center City of Hope
  136. Compugen
  137. Concortis Biotherapeutics
  138. Cormorant Asset Management
  139. Cornell University
  140. Creative Biolabs
  141. Credit Suisse First Boston Next Fund
  142. Crescendo Biologics
  143. Crocker Ventures
  144. CTI Life Sciences Fund
  145. Cytogen
  146. CytomX Therapeutics
  147. Cytovance Biologics
  148. Daiichi Sankyo
  149. Dalton Pharma Services
  150. Dana-Farber Cancer Institute
  151. Dansk Erhvervsinvestering
  152. Debiopharm
  153. Deerfield  Management
  154. Division of Rheumatology, Michigan Medicine
  155. Dophen Biomed
  156. Dow Employees’ Pension Plan
  157. Dow Venture Capital
  158. Duke University
  159. Duquesne Capital Management
  160. ECOG-ACRIN Cancer Research Group
  161. EirGenix
  162. Eisai
  163. Elder Pharmaceuticals
  164. Eleven Biotherapeutics
  165. Eli Lilly
  166. Endo Pharmaceuticals
  167. Esperance Pharmaceuticals
  168. ETH Zurich
  169. Eucodis Bioscience
  170. Evonik
  171. Expansion Venture Capital
  172. Extend Biopharma
  173. Fabrus
  174. Ferring Pharmaceuticals
  175. Ferro Pfanstiehl Laboratories
  176. Fidelity Management & Research Company
  177. Fonds de solidarité FTQ
  178. Formation Biologics
  179. Formosa Laboratories
  180. For-Robin
  181. Fortis Therapeutics
  182. Fosun Pharma
  183. Fox Chase Cancer Center
  184. Fred Alger Management
  185. Fred Hutchinson Cancer Research Center
  186. Freeman Hospital
  187. FUJIFILM Diosynth Biotechnologies
  188. Genentech
  189. Genmab
  190. Genzyme
  191. German Hodgkin Study Group
  192. Gilead Sciences
  193. GlaxoSmithKline (GSK)
  194. Global Bio-Chem
  195. Glykos
  196. Glynn Capital
  197. Glythera
  198. Goodwin Biotechnology
  199. GTC Biotherapeutics
  200. Guardant Health
  201. Guy’s and St. Thomas’ NHS Foundation Trust
  202. H. Lee Moffitt Cancer Center & Research Institute
  203. Halozyme
  204. Hambrecht & Quist Capital Management
  205. Hangzhou DAC Biotech
  206. Hartmann Oncology Radiotherapy Group
  207. HBM Healthcare Investments
  208. HBM Partners
  209. HealthCap
  210. Heidelberg Pharma
  211. Heraeus Precious Metals
  212. Hercules Capital
  213. HNI Corporation
  214. Hôpital Necker-Enfants Malades
  215. HOPU Investment Management
  216. Hospital Clinic of Barcelona
  217. Hospital General de Valencia
  218. Hospital La Fe
  219. Hospital St. Louis
  220. Hospital Universitario de Salamanca
  221. Houston Methodist Cancer Center
  222. Houston Methodist Hospital
  223. Humanwell Healthcare
  224. iBIOSOURCE
  225. IDT Australia
  226. IDT Biologika
  227. Igenica Biotherapeutics
  228. ImClone Systems
  229. Immatics
  230. ImmunoGen
  231. Immunomedics
  232. INC Research
  233. Index Ventures
  234. Indiana University School of Medicine
  235. Indiana University Simon Cancer Center
  236. Innate Pharma
  237. Innovate UK
  238. Innovis Investments
  239. Institut Bergonié
  240. Institut Curie - Hôpital René Hugenin
  241. Institut de Cancérologie de Lorraine (ICL)
  242. Institut Jules Bordet
  243. International Biotechnology Trust
  244. International College of Manitoba (ICM)
  245. Invenra
  246. IONTAS
  247. IRCCS AOU San Martino
  248. Iroquois Capital Group
  249. Istituto di Ematologia di Bologna
  250. IU Health Goshen Center for Cancer Care
  251. JAFCO
  252. Janssen Biotech
  253. Jennison Associates
  254. Johns Hopkins University
  255. Johnson & Johnson
  256. Jonsson Comprehensive Cancer Center
  257. Kairos Therapeutics
  258. Kaplan Medical Center
  259. Karmanos Cancer Institute
  260. Karolinska University Hospital
  261. Kemwell Biopharma
  262. Kolltan Pharmaceuticals
  263. Korea Cancer Center Hospital
  264. Kumamoto University Hospital
  265. Kyowa Hakko Kirin
  266. Lead Discovery Center
  267. LegoChem Biosciences
  268. Lehigh University
  269. Leica Biosystems
  270. Ligand Pharmaceuticals
  271. Lilly Ventures
  272. LinXis
  273. LODH Private Equity
  274. Lombard Odier
  275. Lonza
  276. Loyola University
  277. Lumira Capital
  278. Lymphoma Study Association (LYSA)
  279. MAB Discovery
  280. MabPlex
  281. MabSpace Biosciences
  282. MabVax Therapeutics
  283. MacroGenics
  284. Masonic Cancer Center
  285. Massachusetts General Hospital
  286. Massey Cancer Center
  287. Maverick Capital
  288. Max Planck Innovation
  289. Mayo Clinic
  290. MD Anderson Cancer Center
  291. Medarex
  292. MediaPharma
  293. Medical College of Wisconsin
  294. MedImmune
  295. Meditope Biosciences
  296. Medivation
  297. MedStar Washington Hospital Center
  298. Memorial Sloan Kettering Cancer Center
  299. Menarini Group
  300. Merck Serono
  301. Merrimack Pharmaceuticals
  302. Mersana Therapeutics
  303. Millennium Pharmaceuticals
  304. MImAbs
  305. Minomic
  306. Mitsubishi Tanabe Pharma
  307. Modal Capital Partners
  308. Morphotek
  309. MPM Capital
  310. MS Seed Capital
  311. MS Ventures
  312. MultiCell Immunotherapeutics
  313. Nantes University Hospital
  314. Natco Pharma
  315. National Cancer Center of Korea
  316. National Cancer Institute
  317. National Research Council of Canada
  318. NBE Therapeutics
  319. Nerviano Medical Sciences
  320. New Enterprise Associates
  321. New York Medical College
  322. Nextech Venture
  323. Noonday Asset Management
  324. Nordic Nanovector
  325. Norfolk and Norwich University Hospital
  326. Northeast Securities Prosperity Healthcare Fund
  327. Northwestern University
  328. Novartis
  329. Novartis Venture Fund
  330. Novasep
  331. Novella Clinical
  332. Novimmune
  333. NSABP Foundation
  334. OBI Pharma
  335. OGD2 Pharma
  336. Ohio State University
  337. Oncology Institute of Southern Switzerland
  338. Oncotec Pharma Produktion
  339. Onyx Pharmaceuticals
  340. OPKO Health
  341. OrbiMed Advisors
  342. OrbiMed Associates
  343. Oregon Health and Science University
  344. Orphan Medical
  345. Osage University Partners
  346. Oslo University Hospital
  347. OVP Venture Partners
  348. Oxford BioTherapeutics
  349. Oxford Capital Partners
  350. Oxford Finance
  351. Oxis Biotech
  352. Pacific GMP
  353. Particle Sciences
  354. Patheon
  355. Perceptive Advisors
  356. PETHEMA Foundation
  357. Pfizer
  358. Pfizer Venture Investments
  359. Pharmacyclics
  360. PharmaMar
  361. Philochem
  362. Philogen
  363. Pierre Fabre
  364. Piramal Pharma Solutions
  365. Policlinico S. Orsola-Malpighi
  366. PolyTherics
  367. PrECOG
  368. Presidio Partners
  369. Princess Margaret Hospital
  370. ProBioGen
  371. Progenics Pharmaceuticals
  372. ProJect Pharmaceutics
  373. ProLynx
  374. PSI Company
  375. Purdue University
  376. QPS Holdings
  377. Quanta BioDesign
  378. Queen Elizabeth Hospital
  379. Ramot
  380. Recepta Biopharma
  381. Redmile Group
  382. Redwood Bioscience
  383. Redwood Pharma
  384. Regeneron Pharmaceuticals
  385. Regional Center for the Fight Against Cancer
  386. RemeGen
  387. ReqMed Company
  388. Research Corporation Technologies
  389. Roche
  390. Roche Venture Fund
  391. Rock Springs Capital Management
  392. Roswell Park Cancer Institute
  393. Royal Hospital for Children Glasgow
  394. Royal Liverpool Hospital
  395. Samsung Medical Center
  396. Sandoz
  397. Sanofi-Aventis
  398. Sapienza University of Rome
  399. Sapporo Medical University
  400. Sarah Cannon Research Institute
  401. Scale Venture Partners
  402. Schering-Plough
  403. SCIEX
  404. Scottish Widows Investment Partnership
  405. SCRI Innovations
  406. SEASUN BIOMATERIALS
  407. Seattle Cancer Care Alliance
  408. Seattle Genetics
  409. Seoul National University Hospital
  410. Serina Therapeutics
  411. Severance Hospital
  412. Shanghai Fosun Pharmaceutical
  413. Shanghai Rui Jin Hospital
  414. Shenogen
  415. Sigma-Aldrich
  416. Silicon Valley Bank
  417. Sinopharm Capital
  418. Skyline Ventures
  419. Societa Italiana Corticosteroidi
  420. Sofinnova Ventures
  421. Sorenson Development
  422. Sorrento Therapeutics
  423. SOTIO
  424. South East Growth Fund & Management
  425. Southampton General Hospital
  426. Southwest Oncology Group
  427. Spectrum Pharmaceuticals
  428. Spirogen
  429. SR One
  430. St James University Hospital
  431. St. Catherine of Siena Medical Center
  432. St. Joseph's Health Care
  433. St. Jude Children's Research Hospital
  434. Stanford University
  435. State University of New York
  436. Stemcentrx
  437. SUEZ Ventures
  438. Sutro Biopharma
  439. SV Life Sciences
  440. Symbiosis Pharmaceutical Services
  441. Symphogen
  442. Synaffix
  443. Syndivia
  444. Syngene
  445. Syntarga
  446. Synthon
  447. Synthon Biopharmaceuticals
  448. Synthorx
  449. Tagworks Pharmaceuticals
  450. Takeda Oncology
  451. Takeda Pharmaceutical
  452. Tavistock Life Sciences
  453. Tekla Healthcare Investors
  454. Tekla Life Science Investors
  455. The Chemistry Research Solution
  456. The Christie NHS Foundation Hospital
  457. The Cleveland Clinic
  458. The Column Group
  459. The Royal Marsden NHS Foundation Trust
  460. The Scripps Research Institute
  461. The Scripps Research Institute
  462. The Wild Family Office
  463. Themelios Ventures Partners
  464. Theranyx
  465. Thiel Capital
  466. ThioLogics
  467. Third Rock Ventures
  468. TPG-Axon Capital
  469. Triphase Accelerator
  470. Tube Pharmaceuticals
  471. Tubulis Technologies
  472. Tulane University
  473. Twilight Venture Partners
  474. UNC Lineberger Comprehensive Cancer Center
  475. Unilever Technology Ventures
  476. Union Carbide Employees’ Pension Plan
  477. United Therapeutics
  478. Universitair Medisch Centrum
  479. Universitair Ziekenhuizen Leuven
  480. University Hospital Bern
  481. University Hospital Dresden
  482. University Hospital of Udine
  483. University Hospital of Wales
  484. University Hospital Ramon y Cajal
  485. University Hospitals Seidman Cancer Center
  486. University of Alabama
  487. University of Arizona
  488. University of California
  489. University of Cologne
  490. University of Copenhagen
  491. University of Georgia
  492. University of Kansas Medical Center Research Institute
  493. University of Miami
  494. University of Minnesota
  495. University of Munich
  496. University of New Mexico Cancer Center
  497. University of Nottingham
  498. University of Oklahoma Stephenson Cancer Center
  499. University of Pennsylvania Abramson Cancer Center (ACC)
  500. University of Pittsburgh
  501. University of Rochester Medical Center
  502. University of Texas Health Science Center
  503. University of Ulm
  504. University of Washington Cancer Consortium
  505. University of Western Ontario
  506. US Oncology Research
  507. UT Southwestern Medical Center
  508. Valeant Pharmaceuticals
  509. Vanderbilt-Ingram Cancer Center
  510. Venrock Healthcare Capital Partners
  511. Ventana Medical Systems
  512. Venture Associates
  513. Venture West
  514. Ventures West
  515. Versailles Hospital
  516. Versant Ventures
  517. Vertex Ventures
  518. Victor Hugo Surgical Clinic
  519. Virginia Cancer Specialists
  520. Visterra
  521. VivaMab
  522. Vivo Capital
  523. VLG Investments
  524. VU University Medical Center Amsterdam
  525. Vulcan Capital
  526. Wake Forest University Health Sciences
  527. Washington University School of Medicine
  528. Waters Corporation
  529. Watson Pharmaceuticals
  530. Weill Medical College of Cornell University
  531. Wellington Management Company
  532. Western Regional Medical Center
  533. Wharton Biotechnology Partners
  534. WILEX
  535. Wilmot Cancer Institute
  536. Wntrix
  537. WT Investment Advisors Fund
  538. WuXi AppTec
  539. Wyeth
  540. Xencor
  541. Xintela
  542. Yale University
  543. Yuhan Corporation
  544. Zhejiang Medicine
  545. Ziff Asset Management
  546. Zymeworks
  547. ZymoGenetics

You may also like

Copyright © Roots Analysis. All Rights Reserved.
website security